240 related articles for article (PubMed ID: 37293258)
1. Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting.
Skafida E; Andrikopoulou A; Terpos E; Markellos C; Moustafa S; Pectasides D; Dimopoulos MA; Zagouri F; Vassilopoulos D
Breast J; 2023; 2023():3614296. PubMed ID: 37293258
[TBL] [Abstract][Full Text] [Related]
2. Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review.
Andrikopoulou A; Fiste O; Liontos M; Dimopoulos MA; Zagouri F
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530456
[TBL] [Abstract][Full Text] [Related]
3. Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Roberts KE; Rickett K; Feng S; Vagenas D; Woodward NE
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012988. PubMed ID: 31994181
[TBL] [Abstract][Full Text] [Related]
4. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Roberts KE; Adsett IT; Rickett K; Conroy SM; Chatfield MD; Woodward NE
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013167. PubMed ID: 35005781
[TBL] [Abstract][Full Text] [Related]
6. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
Hyder T; Marino CC; Ahmad S; Nasrazadani A; Brufsky AM
Front Endocrinol (Lausanne); 2021; 12():713700. PubMed ID: 34385978
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience.
Andrikopoulou A; Fiste O; Apostolidou K; Skafida E; Markellos C; Liontos M; Kyriazoglou A; Dimopoulos MA; Zagouri F
Med Sci (Basel); 2021 Jun; 9(2):. PubMed ID: 34198899
[TBL] [Abstract][Full Text] [Related]
8. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
9. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis.
D'Onofrio R; Sperduti I; Piacentini F; Barbolini M; Omarini C; Toss A; Cortesi L; Barbieri E; Canino F; Dominici M; Moscetti L
Clin Breast Cancer; 2023 Dec; 23(8):e534-e541. PubMed ID: 37775349
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
14. Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting.
Abdel-Razeq H; Sharaf B
Drug Des Devel Ther; 2022; 16():727-735. PubMed ID: 35321498
[TBL] [Abstract][Full Text] [Related]
15. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
[TBL] [Abstract][Full Text] [Related]
16. The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
Shanmugam VK; McCloskey J; Elston B; Allison SJ; Eng-Wong J
Breast Cancer Res Treat; 2012 Jan; 131(2):699-708. PubMed ID: 22076476
[TBL] [Abstract][Full Text] [Related]
17. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of arthralgia with estrogen deprivation.
Lintermans A; Neven P
Steroids; 2011 Jul; 76(8):781-5. PubMed ID: 21377484
[TBL] [Abstract][Full Text] [Related]
19. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
20. Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands.
Luyendijk M; Blommestein H; Uyl-de Groot C; Siesling S; Jager A
JAMA Netw Open; 2023 Feb; 6(2):e2256170. PubMed ID: 36795415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
